ConductScience.org, home

Paper33352201

Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.

Yhim HY and 10 others. Ann Oncol, 2021. Cited by 26 papers, by iCite.

Cite this record

ConductScience Library. Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial. Papers, record 33352201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33352201

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
PubMed
Journal
Ann Oncol
PubMed
Year
2021
PubMed
Publication types
Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
1.45
iCite
Revised in PubMed
2022-12-07
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yhim HYH-Y
2Kim TT
3Kim SJS J
4Shin HJH-J
5Koh YY
6Kim JSJ S
7Park JJ
8Park GSG S
9Kim WSW S
10Moon JHJ H
11Yang DHD-H

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lymphoma, T-Cell, PeripheralMajor topic
Deoxycytidine
Humans
Neoplasm Recurrence, Local
Pyrimidines
Quinazolines
Treatment Outcome
Gemcitabine

Source PubMed

Download CSV of topics

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
41975188Annexin A3 potentiates lenvatinib resistance in hepatocellular carcinoma through multiple approaches amplified by a positive feedback loop.Cell Death Dis2026https://conductscience.org/library/papers/41975188PubMed
41535417Unraveling the many faces of angioimmunoblastic T-cell lymphoma: clinical, pathological, and molecular heterogeneity.Ann Hematol2026https://conductscience.org/library/papers/41535417PubMed
41394820Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma.Front Immunol2025https://conductscience.org/library/papers/41394820PubMed
41105775Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.Sci Adv2025https://conductscience.org/library/papers/41105775PubMed
40098700Advancing the understanding and management of angioimmunoblastic T-cell lymphoma: insights into its pathogenesis, clinical features, and emerging therapeutic strategies.Front Oncol2025https://conductscience.org/library/papers/40098700PubMed
39175124Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma.Chin Med J (Engl)2024https://conductscience.org/library/papers/39175124PubMed
38824603Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.J Hematol Oncol2024https://conductscience.org/library/papers/38824603PubMed
38486980Small-molecule agents for cancer immunotherapy.Acta Pharm Sin B2024https://conductscience.org/library/papers/38486980PubMed
37596643PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.Mol Cancer2023https://conductscience.org/library/papers/37596643PubMed
37188182Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL).Front Oncol2023https://conductscience.org/library/papers/37188182PubMed
36900160Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma.Cancers (Basel)2023https://conductscience.org/library/papers/36900160PubMed
36773078Development and safety of PI3K inhibitors in cancer.Arch Toxicol2023https://conductscience.org/library/papers/36773078PubMed
36765544Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma.Cancers (Basel)2023https://conductscience.org/library/papers/36765544PubMed
35626087Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders.Cancers (Basel)2022https://conductscience.org/library/papers/35626087PubMed
35565460Peripheral T-Cell Lymphomas: Therapeutic Approaches.Cancers (Basel)2022https://conductscience.org/library/papers/35565460PubMed
34072040Targeted Approaches to T-Cell Lymphoma.J Pers Med2021https://conductscience.org/library/papers/34072040PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TSC27249PubTator's text mininghttps://conductscience.org/library/genes/7249

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33352201

GET https://conductscience.org/api/papers/v1/33352201/authors